

PrescQIPP work plan 2023-5 (two-year rolling work plan)

Bulletin name	Description	Category *see below	Quality assurance process planned quarter							
			Q1 Apr - Jun 2023	Q2 Jul - Sep 2023	Q3 Oct - Dec 2023	Q4 Jan to Mar 2024	Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025
Sustainability in medicines optimisation	A resource looking at areas other than inhalers for sustainability in prescribing and medicines optimisation, e.g. insulin pens and devices. Options to improve recycling, refillable pens vs pre-filled pens of insulin. Include safer inhaler disposal and how to make it happen/showcasing projects across the country that have worked. Lists of recycling schemes available for patients to recycle their plastics from medicines	N								
Teratogenic drugs	Bulletin to identify potentially teratogenic drugs and avoiding use in women of child bearing age. Patient level data in data pack to show number of women of child bearing age prescribed these drugs. Bulletin will signpost to sources of information on medicines in pregnancy; develop searches for pregnancy + drugs at highest risk; patient level data, e.g. female plus high risk drug. Sign post to BUMPS for leaflets. Focus on drugs with specific MHRA warnings and risk management tools rather than duplicate what's already out there.	C								
Reviewing high cost high impact items	An analysis of the highest cost impact items - together with evidence base and/or cost-effectiveness, quick wins on any savings available. Webinar on how to use PrescQIPP resources to help identify these.	C								
Over-medication	To include implementation of STOMPLD guidance and reducing inappropriate prescribing of antipsychotics in dementia	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Description	Category *see below	Quality assurance process planned quarter							
			Q1 Apr - Jun 2023	Q2 Jul - Sep 2023	Q3 Oct - Dec 2023	Q4 Jan to Mar 2024	Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025
Gender dysphoria	Hormone treatments for gender dysphoria, prescribing guidance and shared care arrangements. A national SCG for gender dysphoria would be hugely beneficial as there are few specialist centres, none of whom seem to have adopted the same practices. May be delayed in view of NHSE consultation/Cass review etc, will await finalisation from NHSE first.	C								
Insulin	Review of insulin use in diabetes, treatment choices and pathway.	C								
Reducing health inequalities	Identification of high impact areas that medicines management teams could make a real difference to in terms of reducing health inequalities. Need impact tool to show local health inequality at PCN/ practice level and cost of intervention. Might need to focus on one area only, such as hypertension case finding.	N								
Nutrition	Guidance to support clinicians in challenging preconceptions about nutrition prescribing.	C								
Carbon literacy training	Commission an expert company to provide a carbon literacy training course for healthcare professionals. This will be delivered through a series of webinars.	S								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Description	Category *see below	Quality assurance process planned quarter							
			Q1 Apr - Jun 2023	Q2 Jul - Sep 2023	Q3 Oct - Dec 2023	Q4 Jan to Mar 2024	Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025
Avoiding look alike, sound alike (LASA) errors through safer prescribing	LASA errors - already covered in community pharmacy, this resource would cover how to address this at the point of prescribing. The NPA has produced a leaflet in Aug 2021. Also consideration of adopting Tall Man lettering - is this something which could be added to GP practice clinical systems to enable prescribers to choose the correct product? There may also be some research around how many letters you type into the drug search when prescribing, i.e. choosing more letters (min 5) should help to reduce the number of different products brought up on the database.	C								
Anticholinergic burden	Update to existing bulletin. Addition of any new tools, e.g. MediChec to calculate ACB score, what further evidence is available. Deprescribing algorithms	C								
Asthma	Update to existing bulletin New inhalers, costs change regularly, include Wales update, More info on carbon-friendly inhalers, Trimbaw (with the LAMA glycopyronium is now licenced for asthma) . Can delete mention of MURS in community pharmacy etc. PQS, NICE asthma inhaler decision aid and use of biologics in secondary care. Develop a review tool for those patients prescribed triple therapy inhalers (for COPD or Asthma) to enable assessment against current NICE and/or GOLD clinical guidance. Include any changes arising from NICE guidance due to be published July 2024	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Description	Category *see below	Quality assurance process planned quarter							
			Q1 Apr - Jun 2023	Q2 Jul - Sep 2023	Q3 Oct - Dec 2023	Q4 Jan to Mar 2024	Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025
Covert administration	Update on LPS as still not come into force in place of DoLS. Consider SMR as first step in process. Consider any new references. Consider adding CQC recommendations for which information to record https://www.cqc.org.uk/guidance-providers/adult-social-care/covert-administration-medicines	C								
Emollients	Update to bulletins 228,239 and 240 and 181 combining care homes and emollients and fire risk guidance into one overarching emollients bulletin. Include self care, Include cost effective barrier creams (update to bulletin 181) and when to deprescribe emollients Consider implementing risk assessments for assessing potential fire hazard risks. Available products and pricing. Update in line with new products and cost comparison charts, to fit with other new skin bulletins.	N								
Chronic heart failure	Update to current bulletin. Recommendations for sodium glucose co-transporter 2 inhibitors, and imminent NICE guidance	C								
Dental products on FP10	Update to include to include advice patients with cancer (caries prevention in head and neck cancer) and prescribing of artificial saliva products.	N								
Dependence forming medicines	Update pulling all resources together, include patient friendly resources. Consider new NG215 and non-pharmacological resources to support management. Include an update to hypnotics bulletin	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Description	Category *see below	Quality assurance process planned quarter							
			Q1 Apr - Jun 2023	Q2 Jul - Sep 2023	Q3 Oct - Dec 2023	Q4 Jan to Mar 2024	Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025
Lancets	Update with new products and prices such as Fastclix (with contains pre-loaded lancets drum that retracts?) more cost effective alternative to safety lancets. Could be refreshed and republished.	Q								
Medicines formulary and shared care guidance development across integrated care systems	Update to include links to RMOC/NHSE shared care protocols published in 2022. Include shared care, long term plan.	N								
Medicines waste	To include the environmental impact of waste medicines rather than just cost. Patient facing campaign materials. Ensure covers medication waste in care homes and how this could be minimised. Link with sustainability strategy.	N								
Medicines without harm	Link in to national safety programme to avoid duplication.	C								
NSAIDs	Update to include cost comparison charts. Could be refreshed and republished.	C								
Point of care testing	Update. Consider community pharmacy testing and clear directions regarding genomic testing program.	N								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Description	Category *see below	Quality assurance process planned quarter									
			Q1 Apr - Jun 2023	Q2 Jul - Sep 2023	Q3 Oct - Dec 2023	Q4 Jan to Mar 2024	Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025		
Polypharmacy and deprescribing	NG56 key therapeutic topic indicators withdrawn. Add information from national overprescribing report. Update links and add new tools.	C										
PPI- long term safety and gastroprotection	Cost comparison charts, latest availability of H2RA. Link to deprescribing algorithms. Refresh and republish this is no new evidence.	C										
Commissioning medicines in service redesign	Update to incorporate new structures and landscape.	N										
Antiepileptic drugs: Appropriate switching to generics or brand equivalents	Update in line with new NICE guidance on anti-epileptics. Important safety information. Addition of new antiepileptics.	C										
Antioxidant vitamins for AMD	It may be possible to review and republish this one and freshen the data pack.	Q										

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Description	Category *see below	Quality assurance process planned quarter							
			Q1 Apr - Jun 2023	Q2 Jul - Sep 2023	Q3 Oct - Dec 2023	Q4 Jan to Mar 2024	Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025
Bisphosphonate treatment for osteoporosis	Update and include length of treatment for different drugs. Add information re denosumab in the light of MHRA alert on rebound fractures. Updating pathways with addition of new drug Romosozumab. Include new National Osteoporosis guidelines. Title of new resource would be Osteoporosis. Easy pictogram would be useful. Capture zoledronic use between primary and secondary care to ensure duplication does not happen and appropriate follow up happens.	C								
Domiciliary care	Review and update. Potential to cover appropriate/inappropriate dosette use (link to monitored dosage systems bulletin), reconciliation, training.	N								
Transferring patients between care settings	Review. Tie in with Discharge Medicines Service? Medicines reconciliation in care homes; medication reviews on discharge into care home? Reflect new NHS structure in update.	N								
Continence	Update and include a section on intermittent self catheterisation and cost effective treatment choices. Review and update if necessary. Could it include use of pads – frequency of changing – prevention of sores – maintenance of skin integrity. Update in line with new NICE guidance.	C								
Controlled drugs monitoring	It may be possible to review and republish this one and freshen the data pack.	N								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Description	Category *see below	Quality assurance process planned quarter							
			Q1 Apr - Jun 2023	Q2 Jul - Sep 2023	Q3 Oct - Dec 2023	Q4 Jan to Mar 2024	Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025
Gluten free	Update the prescribing figures to give a more up to date picture of the current NHS spend. It may be possible to review and republish this one and freshen the data pack	Q								
Lymphoedema compression garments (DROP-List)	Include looking at off FP10 models Include any examples of service re-design, e.g. other procurement methods, outside of primary care prescription	N								
Mesalazine (Branded)	It may be possible to review and republish this one and freshen the data pack	Q								
Omega-3 fatty acid compounds and other fish oils	To update with reference to new NICE TA on omega-3, Consider icosapent ethyl. Include new specialist drugs	C								
Opioid patches	Consider separate bulletins or sections for buprenorphine and fentanyl so it can't be interpreted that the 2 patches are similar/ interchangeable despite differences in potency. Cost comparison would also be helpful. It would be helpful to have information on deprescribing	C								
Oxycodone	It may be possible to review and republish this one and freshen the data pack	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Description	Category *see below	Quality assurance process planned quarter							
			Q1 Apr - Jun 2023	Q2 Jul - Sep 2023	Q3 Oct - Dec 2023	Q4 Jan to Mar 2024	Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025
Private consultation - Prescribing on the NHS following a private consultation	Needs updating, with clear support for GPs in the form of communication/letters. Increasing number of queries from primary care re patients accessing treatment privately and requesting GP to prescribe the recommended medication. Consider change of landscape with waiting times, private treatment.	N								
Stoma	Update and include cost effective choices and patient level data on oversupply. Include cost comparison charts. Include examples of service redesign.	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)